Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.42 |
| ▸ | HTR2A | P28223 | 5/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 4/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3004188 | 0.86 | HTR3A (0.53) | AKT1MEN1KMT2A | |
| SCHEMBL12563577 | 0.85 | MCHR1 (0.46) | MCHR1TP53MAPTHRH4MEN1 | |
| SCHEMBL1989930 | 0.84 | HTR3A (0.45) | MCHR1TP53MAPTHRH4CSF1R | |
| SCHEMBL1991125 | 0.82 | HRH4 (0.55) | SLC6A4HTR2ATP53MAPTHTR2C | |
| SCHEMBL1992679 | 0.77 | MEN1 (0.43) | SLC6A4MAPTMEN1KMT2A | |
| SCHEMBL3238492 | 0.75 | SMN1; SMN2 (0.45) | AKT1MAPTHRH4MEN1KMT2A | |
| SCHEMBL1993141 | 0.71 | HRH4 (0.56) | MAPTHRH4MEN1KMT2A | |
| SCHEMBL1991700 | 0.69 | HRH4 (0.71) | MCHR1HRH4MEN1KMT2A | |
| SCHEMBL15707935 | 0.69 | MCHR1 (0.53) | MCHR1SLC6A4HTR2ATP53MAPT | |
| SCHEMBL1993736 | 0.69 | ALDH1A1 (0.48) | MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011079105-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | WO | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | TPMT, TSLP, THPO | AKT1 3095/4885MCHR1 1461/4885SLC6A4 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.